Skip to content

A Knowledge Graph–Driven Multimodal Framework for Drug–Disease Association Prediction

Aug 2026 · IEEE Transactions on Computational Biology and Bioinformatics · Vol 23, pp. 2257-2268 · 0 citations · 41 references
Medicine

TL;DR

KGDDA is proposed, a multimodal framework designed for drug-disease association prediction that synergistically integrates KGs with medical ontologies, enabling the adaptive capture of intricate drug-disease interactions.

Abstract

Drug repurposing represents a cost-effective strategy to identify novel therapeutic applications for existing pharmaceuticals, circumventing the protracted timelines of traditional drug discovery. While knowledge graph (KG) based methods excel at integrating heterogeneous biomedical data, they often struggle to harmonize high-level domain knowledge with fine-grained molecular mechanisms. We propose KGDDA, a multimodal framework designed for drug–disease association prediction that synergistically integrates KGs with medical ontologies. By leveraging an attention-driven fusion mechanism, KGDDA dynamically merges contextual topological embeddings with ontology-derived priors, enabling the adaptive capture of intricate drug–disease interactions. Extensive evaluations on two benchmark datasets demonstrate that KGDDA consistently outperforms state-of-the-art baselines in both predictive accuracy and generalization. Furthermore, case studies on head and neck cancer and small cell lung cancer validate KGDDA’s ability to provide actionable mechanistic insights, highlighting its potential to accelerate therapeutic discovery and precision medicine.

View source

Similar papers

Aug 2026

A Novel Graph Transformer Framework for Predicting Drug-Disease Associations with Structural Awareness.

SGTL-DDA is proposed, a novel graph transformer framework designed to incorporate structural information and domain-specific knowledge from heterogeneous biological information networks (HBINs) that successfully identifies both known therapeutics and novel repositioning candidates, supported by molecular docking result...

Bowei Zhao, Hui Zhao, Yu-An Huang et al. · 0 citations
Aug 2026

MolADR: Multi-Scale Complementary Learning of Dual-Granularity Molecules and Knowledge Graphs for ADR Prediction in Drug Combinations.

MolADR is proposed, a multiscale complementary learning framework that integrates GNN-based KG learning with dual-granularity molecular cross-attention modeling to combine macro-level biomedical associations with microlevel molecular interaction cues, suggesting its ability to highlight chemically plausible atoms and f...

Yi-Fan Qi, Qing-Wen Ren, Chen-Xu Wang et al. · 0 citations
Book Open access Aug 2026

M²DDI: A Unified Framework for Dynamic Multimodal Fusion in Drug-Drug Interaction Prediction

Empirical evaluation and robustness experiments show that M2DDI maintains high predictive accuracy even when modality-specific information is partially missing, outperforming existing methods under similar conditions and establish M2DDI as an effective and mechanism-aware solution for comprehensive DDI prediction.

Runqing Xu, Siyi Liu, Hao-Yang Li et al. · 0 citations
Aug 2026

Molecular Fragment-Based Graph Isomorphism Networks for Interpretable Prediction of Synergistic Drug Combinations.

Results indicate that FragSyn, through the synergistic design of fragment-level representation and cellular context awareness, provides an effective and interpretable new approach to synergistic drug combination prediction.

Li-Feng Shao, Jianqiang Sun, Hong-Zhan Ma et al. · 0 citations
Book Open access Aug 2026

Expanding Knowledge Boundaries via LLM-Grounded Alignment for Drug Combination Recommendation

L2aCo is a model-agnostic knowledge alignment framework that leverages large language models as external biomedical knowledge sources to expand the effective knowledge boundary for drug combinations and substantially improves generalization for cold-start and long-tail cell lines.

Tengfei Ma, Yuqin He, Zhong-Hao Ren et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.